NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

TerminatedN/A

Sponsor: Pfizer

Conditions: Neuroblastoma

Interventions: lorlatinib

Countries: United States, Australia, New Zealand, Portugal, South Korea, Sweden

The overall goal of this real-world data collection is to assess demographic, clinical characteristics and real-world effectiveness of pediatric neuroblastoma patients treated with lorlatinib through the expanded access program.

Eligibility overview

Sex: ALL

Age: 0 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patient receives lorlatinib through Pfizer's expanded access program for treatment of ALK+ neuroblastoma.
* HCP documentation of at least one tumor assessment of response after patient has had at least one dose of lorlatinib
* Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria:

* Any patient who does not meet any of the inclusion criteria defined in the previous section.

Locations (11)

Philadelphia, Pennsylvania, United States
Westmead, New South Wales, Australia
Camperdown, New South Wales, 2050 Australia, Australia
Auckland, New Zealand
Lisbon, Portugal
Seongnam, South Korea
Seoul, South Korea
Gothenburg, Sweden
Linköping, Sweden
Stockholm, Sweden
Umeå, Sweden